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Introduction
Demyelinating forms of Charcot-Marie-Tooth
(CMT) result from mutations in a number of genes,
the majority of which show an autosomal dominant
pattern of inheritance (Bird, 1993-2016). Recessive
patterns of inheritance are less common. We report
a case of demyelinating CMT resulting from com-
pound heterozygous mutation in the FGD4 gene. This
report is consistent with the ethical guidelines of the
publisher and written informed consent was obtained
from the patient for the publication of this report.
Clinical Presentation
The patient was a 61-year-old Caucasian woman
with progressive unsteadiness since the age of 36..
At age 35, she was diagnosed as having Friedreich’s
ataxia. She had not been followed-up since then.
The patient recalled having dexterity difﬁculties and
frequent falls since the age of 8. She had multiple
foot surgeries. She had a normal birth and normal
milestones.
There was no relevant family history. The patient
had two sisters, who both died of cancer. The patient
reported that her mother had clawed toes but walked
normally in her 90s. Past medical history included
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arterial hypertension and a hip replacement at the age
of 52. The patient was smoking and was not drinking
alcohol excessively.
Examination revealed kyphoscoliosis. Neurological
examination showed normal cranial nerves, apart from
broken pursuit eye movements. There was no nystag-
mus. There was mild ﬁnger to nose ataxia and more
prominent heel to shin and gait ataxia. She could walk
using bilateral support. She had mild pes cavus and
deformed feet. There was bilateral foot drop. Her right
leg was weaker compared with the left, following the
hip replacement. She had distal weakness (MRC 4) in
both hands. She was areﬂexic.
She had severe sensory loss (pinprick and proprio-
ception) in both arms up to the elbows and both legs
up to the knees. Vibration sensation was absent in the
limbs. Romberg’s sign was positive.
Routine blood tests, vitamin B12, folate and
immunology testing were normal or negative. She
had increased thyroglobulin and thyroid peroxidase
antibodies, but thyroid function testing was normal.
Magnetic resonance imaging (MRI) of the brain was
unremarkable.
Nerve conduction studies showed absent sensory
responses. Motor conduction studies showed reduced
amplitudes (0.5–1.2mV) and severely reduced veloci-
ties (8–14m/sec).
Genetic screening for the chromosome 17 dupli-
cation and for mutations in PMP22, MPZ, NEFL,
GDAP1, GJB1, EGR2 and the common mitochon-
drial mutations (MELAS, MERRF and NARP) were
all negative. Next generation sequencing analy-
sis of a panel of 14 genes (GJB1, EGR2, FGD4,
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FIG4, GADP1, LITAF, MPZ, MTMR2, NDRG1, NEFL,
PMP22, PRX, SBF2, SH3TC2) implicated in CMT1
revealed two heterozygous likely pathogenic variants
in FGD4: c.[1192-48_1233del];[1304_1305delinsAA]
p.{(?);(Arg435Gln)]. Neither mutation has been pre-
viously reported on public normal variant databases
(dbSNP, NHLBI, exome variant server and ExAC).
The c.1192-48_1233del p.(?) mutation is a 90 bp
deletion encompassing the intron 9/exon 10 bound-
ary and is predicted to result in a truncated and/or
frameshifted transcript and a loss of function. The
c.1394_1305delinsAA p.(Arg435Gln) missense muta-
tion occurs at a highly conserved amino acid within
the plekstrin homology domain, a domain in which a
pathogenic recessive missense mutation has previ-
ously been reported (p.Arg442His PMID 22734899).
As this missense mutation resides within the 90 bp
deletion in the ﬁrst mutation, we were able to conﬁrm
autosomal recessive inheritance by Sanger sequenc-
ing showing that these two mutations were present
on separate alleles despite not having her parents
DNA available.
Discussion
CMT type 4 is the term commonly used to describe
autosomal recessive CMT1 (ARCMT1) cases although
some also classify the autosomal recessive CMT2
ARCMT2 cases as CMT4 (Rossor et al., 2016). CMT
type 4H is characterized by an early onset (up to the
age of 10 years) demyelinating neuropathy, with slow
progression and scoliosis (Delague, 1993-2016). The
diagnosis is established by the presence of biallelic
FGD4 pathogenic variants.
In the case described here there was no clear fam-
ily history of neuropathy. The presence of kyphosco-
liosis, however, in combination with the very severe
neuropathy as indicated by the nerve conduction
studies pointed towards CMT4.
Sensory ataxia when severe can be difﬁcult to
distinguish from cerebellar ataxia. Nerve conduction
studies in such patients are essential in deciding which
gene panels to pursue based on the type and severity
of the neuropathy. This case also illustrates the need
for up to date review of patients labeled as having
a particular genetic disease prior to the availability of
genetic testing for conﬁrmation.
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